ASX ANNOUNCEMENT

SCOTT R. WARD COMMENCES AS DIRECTOR

12 July 2013

Brisbane, Australia – ImpediMed Limited (ASX: IPD) (“ImpediMed”) announces the appointment of Scott R. Ward to the Board of Directors, consistent with the release in May 2013.

“ImpediMed is very pleased to have Scott on the Board of Directors. Scott Ward’s considerable experience in the medical device industry will be very important to us in the coming years as we go through the emerging growth stage of our journey. His expert knowledge in building and growing medical device companies will enhance our strategic thinking and strengthen our operations” said ImpediMed Chairman Dr. Cherrell Hirst.

Mr. Ward stated, “ImpediMed’s application of bioimpedance to clinically assess the early signs of lymphoedema will improve the quality of life for cancer survivors and I am excited to join the effort to fulfill this mission.”

It is with considerable regret that the Board farewells Director Martin Kriewaldt as he retires from the Board after 8 years of committed service. “The Board joins me in thanking Martin for his long-term dedication and commitment to ImpediMed.” Dr. Hirst said.

For further information contact: Dr. Cherrell Hirst, ImpediMed Chairman
T: +61(7) 3860 3700
M: +61 411556124

About L-Dex®
L-Dex® is a trademark of ImpediMed Limited.

The L-Dex scale is a tool to assist in the clinical assessment of unilateral lymphoedema of arm and leg in women and the leg in men by a medical provider. The L-Dex scale is not intended to diagnose or predict lymphoedema of an extremity.

About ImpediMed
ImpediMed Limited is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed’s primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed has the first medical device with an FDA clearance in the United States to aid health care professionals clinically assess secondary unilateral lymphoedema of the arm and leg in women and the leg in men.